OncoMatch/Clinical Trials/NCT06235203
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
Is NCT06235203 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Neoadjuvant therapy,Toripalimab and Adjuvant therapy in experimental group,Toripalimab for recurrent nasopharyngeal carcinoma.
Treatment: Neoadjuvant therapy,Toripalimab · Adjuvant therapy in experimental group,Toripalimab — A multicenter randomized controlled study of surgery combined with neoadjuvant and adjuvant therapy for locally advanced recurrent nasopharyngeal carcinoma in comparison to surgery combined with adjuvant therapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage RT2, RT3, RT4
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: radiation therapy — definitive
≥6months from the accomplishment of radical radiation to recurrence
Cannot have received: radiation therapy
Exception: previously only 1 course of radiotherapy
previously only 1 course of radiotherapy
Cannot have received: radioactive particle implantation
History of radioactive particle planting
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06235203 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, radioactive particle implantation disqualifies patients from enrollment.
What disease stage is eligible?
Stage RT2 or RT3 or RT4 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages